Posted by Michael Wonder on 27 May 2021
Foresee Pharmaceuticals announces FDA approval of Camcevi for the treatment of advanced prostate cancer; Accord BioPharma to head the U.S. commercialisation
26 May 2021 - Foresee Pharmaceuticals announced today that the U.S. FDA has approved the new drug application for Camcevi 42 mg, a ready to use 6 month subcutaneous depot formulation of leuprolide mesylate, as a treatment of advanced prostate cancer.
The FDA approval was based on a successful Phase 3 trial in 137 Advanced Prostate Carcinoma patients, where treatment with Camcevi 42 mg injection every 6 months was demonstrated to be effective, safe and well tolerated.
